Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2021

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of June 30, 2021 and December 31, 2020 were as follows:


	June 30, 2021		December 31, 2020
Accrued compensation expenses	$	20,242	$	317,068
Accrued research and development		51,246		89,156
Accrued professional fees		1,750,146		49,707
Other accounts payable and accrued expenses		97,005		—
Total	$	1,918,639	$	455,931